| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $296,738 | 10 | 71 |
Sells | $420,178 | 4 | 29 |
| Baltera Robert Jr. | director | 6 | $250,182 | 0 | $0 | $250,182 |
| Williams Donald Allen | director | 4 | $46,556 | 0 | $0 | $46,556 |
| Jones Mitchell Lawrence | Chief Medical Officer | 0 | $0 | 2 | $110,016 | $-110,016 |
| Finley John David | CEO, CFO | 0 | $0 | 2 | $310,161 | $-310,161 |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and …
Over the last 12 months, insiders at Palisade Bio, Inc. have bought $296,738 and sold $420,178 worth of Palisade Bio, Inc. stock.
On average, over the past 5 years, insiders at Palisade Bio, Inc. have bought $98,125 and sold $210,185 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Baltera Robert Jr. (director) — $250,182. Williams Donald Allen (director) — $46,556.
The last purchase of 10,000 shares for transaction amount of $14,600 was made by Williams Donald Allen (director) on 2026‑10‑02.
| 2026-10-02 | Williams Donald Allen | director | 10,000 0.0048% | $1.46 | $14,600 | -2.43% | ||
| 2026-10-01 | Williams Donald Allen | director | 10,000 0.0047% | $1.42 | $14,200 | -1.40% | ||
| 2026-07-09 | Baltera Robert Jr. | director | 25,000 0.0143% | $1.96 | $48,900 | -2.28% | ||
| 2026-07-08 | Baltera Robert Jr. | director | 20,000 0.0112% | $1.99 | $39,798 | -5.85% | ||
| 2026-07-07 | Sale | Finley John David | CEO, CFO | 146,798 0.084% | $2.07 | $303,343 | -6.97% | |
| 2026-07-07 | Sale | Jones Mitchell Lawrence | Chief Medical Officer | 51,880 0.0295% | $2.05 | $106,536 | -6.97% | |
| 2026-07-07 | Baltera Robert Jr. | director | 30,000 0.0169% | $2.03 | $61,044 | -6.97% | ||
| 2026-07-06 | Baltera Robert Jr. | director | 20,000 0.0116% | $2.05 | $41,040 | -4.90% | ||
| 2026-07-02 | Baltera Robert Jr. | director | 10,000 0.0054% | $1.98 | $19,800 | -7.38% | ||
| 2026-07-01 | Baltera Robert Jr. | director | 20,000 0.0116% | $1.98 | $39,600 | -1.02% | ||
| 2026-02-12 | Sale | Finley John David | CEO, CFO | 3,896 0.0026% | $1.75 | $6,818 | +10.92% | |
| 2026-02-12 | Sale | Jones Mitchell Lawrence | Chief Medical Officer | 1,989 0.0013% | $1.75 | $3,481 | +10.92% | |
| 2026-01-16 | Williams Donald Allen | director | 5,000 0.0034% | $1.67 | $8,356 | +14.76% | ||
| 2026-01-09 | Williams Donald Allen | director | 5,000 0.0032% | $1.88 | $9,400 | -4.52% | ||
| 2024-05-28 | Williams Donald Allen | director | 1,000 0.1091% | $4.86 | $4,863 | -49.37% | ||
| 2024-05-24 | Finley John David | CEO, CFO, Director | 1,000 0.0994% | $4.81 | $4,810 | -50.71% | ||
| 2024-02-06 | Finley John David | CEO, CFO, Director | 10,000 0.0819% | $0.47 | $4,692 | -43.76% | ||
| 2024-01-31 | Finley John David | CEO, CFO, Director | 10,000 0.0976% | $0.56 | $5,590 | -56.28% | ||
| 2024-01-31 | Williams Donald Allen | director | 10,000 0.1056% | $0.60 | $6,050 | -56.28% | ||
| 2023-09-27 | Finley John David | CEO, CFO, Director | 15,000 0.1655% | $0.54 | $8,088 | -24.34% |
| Williams Donald Allen | director | 1590294 0.9125% | $1.96M | 7 | 0 | |
| Baltera Robert Jr. | director | 461904 0.265% | $568,141.92 | 6 | 0 | |
| Finley John David | CEO, CFO | 217555 0.1248% | $267,592.65 | 10 | 2 | <0.0001% |
| GARR RICHARD | CEO | 240000 0.1377% | $295,200.00 | 2 | 3 | |
| OLDAKER WILLIAM CLYDE | director | 116939 0.0671% | $143,834.97 | 7 | 0 | |
| CONRON JOHN | Chief Financial Officer | 51364 0.0295% | $63,177.72 | 3 | 0 | |
| Daly Richard J | Chief Executive Officer | 23312 0.0134% | $28,673.76 | 7 | 0 | |
| Hallam Thomas | Chief Executive Officer | 17592 0.0101% | $21,638.16 | 2 | 0 | <0.0001% |
| Dawson Michael John | Chief Medical Officer | 15000 0.0086% | $18,450.00 | 1 | 0 | <0.0001% |
| LLOYD JONES JONATHAN BRIAN | Chief Financial Officer | 7859 0.0045% | $9,666.57 | 2 | 0 | |
| Trenschel Robert J. | director | 0 0% | $0 | 5 | 1 |
$22,710,871 | 107 | 8.53% | $220.62M | |
$6,146,922 | 96 | -4.70% | $233.68M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$54,828,550 | 26 | -13.88% | $201.12M | |
$3,858,993 | 22 | -9.81% | $192.38M |
| Increased Positions | 82 | +1,171.43% | 136M | +113,543.78% |
| Decreased Positions | 2 | -28.57% | 33,777 | -28.24% |
| New Positions | 75 | New | 130M | New |
| Sold Out Positions | <1 | Sold Out | 29,406 | Sold Out |
| Total Postitions | 87 | +1,142.86% | 136M | +113,515.53% |
| Two Sigma Securities, Llc | $74.00 | 0.02% | 29,406 | +13,437 | +84.14% | 2025-09-30 |
| Geode Capital Management, Llc | $67.00 | 0.02% | 26,620 | +1,888 | +7.63% | 2025-09-30 |
| Ubs Group Ag | $49.00 | 0.01% | 19,413 | +19,081 | +5,747.29% | 2025-09-30 |
| Xtx Topco Ltd | $35.00 | 0.01% | 14,085 | -13,252 | -48.48% | 2025-09-30 |
| Newbridge Financial Services Group, Inc. | $33.00 | 0.01% | 13,000 | +2,500 | +23.81% | 2025-09-30 |
| Morgan Stanley | $22.00 | 0.01% | 8,618 | +8,611 | +123,014.29% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $13.00 | <0.01% | 5,396 | +829 | +18.15% | 2025-09-30 |
| Citigroup Inc | $6.00 | <0.01% | 2,347 | +2,347 | New | 2025-09-30 |
| Rockefeller Capital Management L.P. | $1.00 | 0% | 500 | +500 | New | 2025-09-30 |
| Federation Des Caisses Desjardins Du Quebec | $0 | 0% | 100 | 0 | 0% | 2025-09-30 |